The Company expects to have ibogaine manufactured and in use for research by Q4.
The Company expects to have ibogaine manufactured and in use for research by Q4.
MINDCURE makes a CAD$500,000 strategic investment in ATMA Journey Centers, an Alberta-based psychedelics-assisted mental health clinic.
The completed equity investment strengthens ties between MINDCURE and ATMA
The Mental Health Crisis is a huge opportunity for psychedelic drugs. But the BIGGEST potential markets may exist outside of mental health.
Field Trip Health just announced the 3rd largest financing by a psychedelics public company: a CAD$82.875 million bought deal. Here's what it means for investors.
Psychedelic stocks are well off of their 2020 highs. But they are even further from their 2020 lows. Opportunity knocks.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now